Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial

被引:62
|
作者
Pinsky, PF
Kramer, BS
Reding, D
Buys, S
机构
[1] NCI, Div Canc Prevent, Bethesda, MD 20892 USA
[2] NIH, Off Dis Prevent, Off Director, Bethesda, MD 20892 USA
[3] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI 54449 USA
[4] Univ Utah, Sch Med, Dept Internal Med, Div Hematol Oncol, Salt Lake City, UT USA
关键词
ethnic groups; family characteristics; genetic predisposition to disease; neoplasms; questionnaires; sex factors;
D O I
10.1093/aje/kwg043
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The authors analyzed data from almost 150,000 subjects aged 55-74 years enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial who completed a self-administered baseline questionnaire (1993-2001) that included items about family history of cancer. Male respondents reported significantly less family history of cancer than females. The relative underreporting by male respondents relative to females was greater for female family members (28% lower for sisters and 21% lower for mothers) than for male family members (13% lower for brothers and 9% lower for fathers). Black, Hispanic, and Asian respondents reported significantly less family history of cancer than Whites. Reported family history prevalences for parents decreased with respondents' age, while those for siblings increased with respondents' age. The four most commonly reported cancers in families were breast (11.8%), lung (10.1%), colorectal (9.4%), and prostate (7.3%) cancer. Expected prevalences in family members of history of cancer overall and history of specific types of cancer were calculated using incidence rates and life table data obtained from the Surveillance, Epidemiology, and End Results Program. Overall, the ratio of reported cancer rates to expected cancer rates in family members was approximately 0.7. Liver, bone, stomach, and brain cancer had greater-than-average reported:expected ratios, while lymphoma, bladder cancer, melanoma, and testicular cancer had lower-than-average ratios.
引用
收藏
页码:792 / 799
页数:8
相关论文
共 50 条
  • [21] Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
    Jiaqi Huang
    Alison M Mondul
    Stephanie J Weinstein
    Stella Koutros
    Andriy Derkach
    Edward Karoly
    Joshua N Sampson
    Steven C Moore
    Sonja I Berndt
    Demetrius Albanes
    [J]. British Journal of Cancer, 2016, 115 : 1087 - 1095
  • [22] Lung Cancer Risk Prediction: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Models and Validation
    Tammemagi, C. Martin
    Pinsky, Paul F.
    Caporaso, Neil E.
    Kvale, Paul A.
    Hocking, William G.
    Church, Timothy R.
    Riley, Thomas L.
    Commins, John
    Oken, Martin M.
    Berg, Christine D.
    Prorok, Philip C.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (13) : 1058 - 1068
  • [23] Effect of Screening on Ovarian Cancer Mortality The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
    Buys, Saundra S.
    Partridge, Edward
    Black, Amanda
    Johnson, Christine C.
    Lamerato, Lois
    Isaacs, Claudine
    Reding, Douglas J.
    Greenlee, Robert T.
    Yokochi, Lance A.
    Kessel, Bruce
    Crawford, E. David
    Church, Timothy R.
    Andriole, Gerald L.
    Weissfeld, Joel L.
    Fouad, Mona N.
    Chia, David
    O'Brien, Barbara
    Ragard, Lawrence R.
    Clapp, Jonathan D.
    Rathmell, Joshua M.
    Riley, Thomas L.
    Hartge, Patricia
    Pinsky, Paul F.
    Zhu, Claire S.
    Izmirlian, Grant
    Kramer, Barnett S.
    Miller, Anthony B.
    Xu, Jian-Lun
    Prorok, Philip C.
    Gohagan, John K.
    Berg, Christine D.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22): : 2295 - 2303
  • [24] Effect of screening on ovarian cancer mortality in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer randomized screening trial.
    Buys, S. S.
    Partridge, E.
    Black, A.
    Johnson, C.
    Lamerato, L.
    Isaacs, C.
    Reding, D.
    Greenlee, R.
    Kessel, B.
    Fouad, M.
    Chia, D.
    Ragard, L.
    Rathmell, J.
    Hartge, P.
    Pinsky, P.
    Izmirlian, G.
    Xu, J.
    Prorok, P.
    Berg, C. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Effect of Screening on Ovarian Cancer Mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
    Pejovic, Tanja
    Nezhat, Farr
    [J]. JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 2011, 18 (06) : 823 - 825
  • [26] ESTIMATING THE COST FOR PROSTATE CANCER (PCA) SCREENING USING THE PROSTATE, LUNG, COLORECTAL AND OVARIAN CANCER SCREENING TRIAL DATA
    Crawford, D.
    Qureshi, Z.
    Mittmann, N.
    Kattan, M.
    Dickson, M.
    Andriole, G. L.
    Reding, D.
    Bennett, C.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A151 - A151
  • [27] Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: Results from 4 years of annual screening in a randomized trial
    Partridge, Edward E.
    Kreimer, Aimee R.
    Buys, Saundra S.
    Reding, Douglas J.
    Fouad, Mona N.
    Riley, Thomas L.
    Greenlee, Robert T.
    Williams, Craig
    Prorok, Philip C.
    Xu, Jian-Lun
    [J]. GYNECOLOGIC ONCOLOGY, 2007, 104 (03) : S14 - S15
  • [28] Prostate cancer screening in the prostate, lung, colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial
    Andriole, GL
    Levin, DL
    Crawford, ED
    Gelmann, ER
    Pinsky, PF
    Chia, D
    Kramer, BS
    Reding, D
    Church, TR
    Grubb, RL
    Izmirlian, G
    Ragard, LR
    Clapp, JD
    Prorok, PC
    Gohagan, JK
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (06) : 433 - 438
  • [29] Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial
    Buys, SS
    Partridge, E
    Greene, MH
    Prorok, PC
    Reding, D
    Riley, TL
    Hartge, P
    Fagerstrom, RM
    Chia, D
    Izmirlian, G
    Fouad, M
    Ragard, LR
    Johnson, CC
    Gohagan, JK
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 193 (05) : 1630 - 1639
  • [30] Recruitment methods employed in the prostate, lung, colorectal, and ovarian cancer screening trial
    Gren, Lisa
    Broski, Karen
    Childs, Jeffery
    Cordes, Jill
    Engelhard, Deborah
    Gahagan, Betsy
    Gamito, Eduard
    Gardner, Vivien
    Geisser, Mindy
    Higgins, Darlene
    Jenkins, Victoria
    Lamerato, Lois
    Lappe, Karen
    Lowery, Heidi
    McGuire, Colleen
    Miedzinski, Mollie
    Ogden, Sheryl
    Tenorio, Sally
    Watt, Gavin
    Wohlers, Bonita
    Marcus, Pamela
    [J]. CLINICAL TRIALS, 2009, 6 (01) : 52 - 59